Fig. 3.

Administration of IT-101 (5 mg/kg, i.v., qwk × 3) and (10 mg/kg, i.v., qwk × 3) to animals bearing three distinct s.c. human lymphoma xenografts can result in significant better survival as compared to CPT-11. Treatments were initiated at 10, 4, and 16 days after subcutaneous injection of Daudi cells, Karpas 299 cells, and L540 cells, respectively. Treatment arms included untreated control (■), CPT-11 (100 mg/kg, i.p., qwk × 3) (◇), IT-101 (5 mg/kg, i.v., qwk × 3) (○), and IT-101 (10 mg/kg, i.v., qwk × 3) (x). The tumor burden was monitored longitudinally by physical measurements. Using Kaplan-Meier method, the survival curves were plot for each treatment group and the log-rank test was used to compare the percent animal survival between treatment groups. In Daudi tumors and L540 tumors, a significant difference between the groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg, i.v., × 3) was not observed. However, these two treatment groups achieved significantly better survival as compared to the groups treated with CPT-11 (P < 0.0001 and P < 0.0001, respectively). In Karpas 299 tumors, no significant difference between the groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg, i.v., qwk × 3) was observed; but animals treated with IT-101 at (10 mg/kg, i.v., qwk × 3) had significantly better survival as compared to those treated with CPT-11. (P = 0.0072). Points indicate mean survival.